Obesity

The rate of obesity-related cardiovascular deaths tripled from 1999 to 2020 — a rise that has taken the greatest toll on underrepresented groups, according to a study.

An investigational aldosterone synthase inhibitor was associated with clinically significant reductions in automated office BP for people with uncontrolled hypertension, with the greatest effects seen in people with concomitant obesity.

CV deaths related to obesity increased by 200% across all race groups from 1999 to 2020, a statistic researchers said reflects the health consequences of the rising burden of obesity in the United States.

Obesity reduced the odds for ICU mortality among patients with acute respiratory distress syndrome receiving extracorporeal membrane oxygenation, according to results published in American Journal of Respiratory and Critical Care Medicine.

Last year, the CDC updated its 22-year-old pediatric BMI-for-age growth charts to add BMIs above the 97th percentile for the first time in order to track severe obesity in children aged 2 to 19 years.

Researchers estimated that semaglutide could cut the obesity prevalence in the United States by about 46% and prevent more than 1.5 million CVD events over 10 years when given to eligible patients with overweight or obesity.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

According to results published in the Journal of Arthroplasty, patients with obesity had greater improvements in patient-reported outcome measures after total knee arthroplasty compared with patients without obesity.